Navigation Links
VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
Date:2/26/2008

SAN FRANCISCO, Feb. 26 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president, chief financial officer of VIA, will present a company update at the Susquehanna Second Annual SIGnificant Options in Healthcare on Tuesday, March 4, 2008, at 1:30 p.m. ET at the W Hotel in New York. Interested parties may access a live audio webcast of the presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

Also on March 4, Lawrence K. Cohen, Ph.D., chief executive officer of VIA, will be speaking at the Rodman & Renshaw Straight to the Heart Cardiovascular Investor Mini Conference in Boston, at the Boston Harbor Hotel.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lotus Pharmaceuticals Raises $5 Million in Private Placement
2. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
3. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
4. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
5. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
6. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
7. NUCRYST Pharmaceuticals announces year-end results
8. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
9. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
10. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
11. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... Delaware farmer Rick Dickerson attended the 2017 Soybean Leadership College ... a thousand acres of soybeans, corn and wheat, and raises peas, sweet corn, baby ... for the fresh market. He also operates a roadside stand and raises broilers for ...
(Date:1/18/2017)... FORT LAUDERDALE, FL (PRWEB) , ... January 18, ... ... and how to manage it from the number one doctor-recommended OTC antiperspirant, Certain ... population and often go untreated. , Certain Dri created this infographic to explain ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, ... official endurance training and fundraising team, to compete in the Boston Marathon on April ... to finish the world’s oldest annual marathon to join Team V and support the ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)...  Adaptive Sound Technologies, Inc. (ASTI), the leading supplier ... Hyatt Place Nashville/Downtown to deliver the best sleep experience ... machines in over two hundred of its guest rooms. ... of having a great stay is sleeping well," said ... Nashville/Downtown. "We,re pleased to be able to offer our ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology: